Literature DB >> 2988589

Effective dose range of enalapril in mild to moderate essential hypertension.

R Bergstrand, H Herlitz, S Johansson, G Berglund, A Vedin, C Wilhelmsson, H J Gomez, V J Cirillo, J A Bolognese.   

Abstract

The dose-response relationship of enalapril was evaluated in a double-blind, balanced, two-period, incomplete-block study in 91 patients with mild to moderate essential hypertension. Patients were randomly assigned to two of six treatments: placebo, 2.5, 5, 10, 20 and 40 mg/day of enalapril maleate. There were two 3-week treatment periods, each preceded by a 4-week, single-blind placebo washout. Each dose of enalapril produced significant decreases in standing and supine systolic and diastolic blood pressure after 2 and 3 weeks of treatment. There were no significant changes on placebo. There was a significant linear dose response relationship for both mean blood pressure and mean change from baseline in blood pressure (P less than 0.01 for systolic and mean arterial pressure, and P less than 0.05 for diastolic pressure). Enalapril was associated with an increasing dose-response relationship across the 2.5-40 mg/day range. The 2.5 mg/dose is effective in some patients; however, doses greater than or equal to 10 mg/day may be necessary to achieve satisfactory blood pressure control.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988589      PMCID: PMC1463850          DOI: 10.1111/j.1365-2125.1985.tb02687.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Analysis of categorical data by linear models.

Authors:  J E Grizzle; C F Starmer; G G Koch
Journal:  Biometrics       Date:  1969-09       Impact factor: 2.571

2.  Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor "MK-421".

Authors:  H Gavras; J Biollaz; B Waeber; H R Brunner; I Gavras; R O Davies
Journal:  Lancet       Date:  1981-09-12       Impact factor: 79.321

3.  Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I.

Authors:  J Biollaz; M Burnier; G A Turini; D B Brunner; M Porchet; H J Gomez; K H Jones; F Ferber; W B Abrams; H Gavras; H R Brunner
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

Review 4.  Medical intelligence drug therapy: captopril.

Authors:  D G Vidt; E L Bravo; F M Fouad
Journal:  N Engl J Med       Date:  1982-01-28       Impact factor: 91.245

5.  Long-term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild-to-moderate essential hypertension.

Authors:  K O Stumpe; A Overlack; R Kolloch; S Schreyer
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  A comparative pilot study of enalapril, a new converting enzyme inhibitor, and hydrochlorothiazide in essential hypertension.

Authors:  R K Ferguson; P H Vlasses; J D Irvin; B N Swanson; R B Lee
Journal:  J Clin Pharmacol       Date:  1982-07       Impact factor: 3.126

7.  Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.

Authors:  J A Millar; F H Derkx; K McLean; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

8.  Captopril in the treatment of mild essential hypertension.

Authors:  A Fernandez-Cruz; M Luque Otero; C Fernandez Pinilla; N Martell Claros
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

9.  Captopril in essential hypertension.

Authors:  E Rabinad Estrada; M Ingelmo Morin; A Martinez Amenos; J Alsina; A Balcells Gorina
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

10.  The clinical pharmacology of enalapril.

Authors:  H J Gomez; V J Cirillo; K H Jones
Journal:  J Hypertens Suppl       Date:  1983-10
View more
  7 in total

1.  Antihypertensive duration of action of cilazapril in patients with mild to moderate essential hypertension.

Authors:  I Kobrin; P Güntzel; R Viskoper; E Paran; R Zimlichman
Journal:  Drugs       Date:  1991       Impact factor: 9.546

2.  Efficacy of enalapril in essential hypertension and its comparison with atenolol.

Authors:  M el Mangoush; N K Singh; S Kumar; A Basha; B S Gupta; Y K Bolya; A Gamati
Journal:  Postgrad Med J       Date:  1990-06       Impact factor: 2.401

3.  Antihypertensive effect of single doses of enalapril in hypertensive patients treated with bendrofluazide.

Authors:  J Webster; D Newnham; O J Robb; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

Review 4.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

5.  Lisinopril dose-response relationship in essential hypertension.

Authors:  H J Gomez; V J Cirillo; J A Sromovsky; E S Otterbein; W C Shaw; J E Rush; S G Chrysant; A H Gradman; A S Leon; E P MacCarthy
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

Review 6.  Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension.

Authors:  Balraj S Heran; Michelle My Wong; Inderjit K Heran; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2008-10-08

Review 7.  Enalapril: a review of human pharmacology.

Authors:  H J Gomez; V J Cirillo; J D Irvin
Journal:  Drugs       Date:  1985       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.